ArticlePloS one2025
A neural network approach to sarcopenia prediction based on bioelectrical impedance in community-dwelling older adults.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to apply a neural network to raw bioelectrical impedance analysis data and to test whether sarcopenia could be predicted with high accuracy. The study population comprised 727 community-dwelling older adults aged 65-85 years who participated in the Kasama Study from 2015 to 2018. Sarcopenia was determined using the standard values set by the Asian Working Group for Sarcopenia 2019. Skeletal muscle mass index, grip strength, and five-times sit-to-stand test (Dataset 1) or skeletal muscle mass index, grip strength, and gait speed (Dataset 2) were used. The characteristic variables were sex, age, height, and body mass index, as well as parameters from bioelectrical impedance analysis, such as reactance, resistance, and impedance for six frequencies (1, 5, 50, 250, 500, and 1000 kHz) in six body parts measured using a multi-frequency body composition analyzer (MC-980A, Tanita). For analysis, a neural network was used to construct a model. For verification of the model's accuracy, a receiver operating characteristic analysis was performed to calculate the sensitivity, specificity, area under the curve, and positive and negative predictive values. Among the participants analyzed, 21 (3.3%) in Dataset 1 and 24 (3.7%) in Dataset 2 had sarcopenia. In Dataset 1, the model that used 5, 50, and 250 kHz showed the highest prediction accuracy (sensitivity: 1.00, specificity: 0.91, area under the curve: 0.96, accuracy: 0.91, positive predictive value: 0.28, negative predictive value: 1.00). In Dataset 2, the model that used 50 kHz exhibited the highest prediction accuracy (sensitivity: 0.91, specificity: 0.84, area under the curve: 0.88, accuracy: 0.84, positive predictive value: 0.17, negative predictive value: 1.00). In conclusion, highly accurate predictions are possible by applying a neural network to the raw data obtained from bioelectrical impedance analysis. As a highly accurate sarcopenia screening method, it is expected to be used in various settings, ranging from clinical practice to local communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.